A Study of Ponsegromab in People With Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 455 participants.

Also called NCT05492500

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose supportive care
Phase
Phase 2
Enrolled
  • 455 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
  • The TIMI Study Group Registry lists this organization as a collaborator
Registry
  • NCT NCT05492500
  • EU CT 2023-509747-27-00
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, China, Czechia, Germany, Hungary, Japan, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05492500. Randomized; quadruple masking; primary purpose supportive care. Start 2022-09-26 (actual); primary completion 2025-03-05 (actual). Results posted on 2026-03-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Ponsegromab in People With Heart Failure
Acronym
GARDEN TIMI 74
Condition
Heart Failure
Intervention (Drug)
Main cohort (Cohort A): Ponsegromab low dose
Intervention (Drug)
Main cohort (Cohort A): Ponsegromab medium dose
Intervention (Drug)
Main cohort (Cohort A): ponsegromab high dose
Intervention (Other)
Main cohort (Cohort A): Matched placebo
Intervention (Drug)
Open-label, PK Cohort (Cohort B): ponsegromab low dose
Intervention (Drug)
Open-label, PK Cohort (Cohort B): ponsegromab medium dose
Intervention (Drug)
Open-label, PK Cohort (Cohort B): ponsegromab high dose
Intervention (Drug)
Optional Cohort C: Ponsegromab low dose
Intervention (Other)
Optional Cohort C: Matched placebo
Intervention (Drug)
Optional Cohort D: Ponsegromab high dose
Intervention (Other)
Optional Cohort D: Matched placebo
Lead sponsor
Pfizer (class: industry)
Collaborator
The TIMI Study Group (class: other)

Record details

Record id
cardio:ct-nct05492500
Content hash
21421ccb08b303eb3ff400b39dc4d762d03f6ed4008036d470c672fb7ebf7604